Isis Pharmaceuticals (ISIS) Reaches New Lifetime High Today
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Isis Pharmaceuticals as such a stock due to the following factors:
- ISIS has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $51.3 million.
- ISIS has traded 1.4 million shares today.
- ISIS is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ISIS with the Ticky from Trade-Ideas. See the FREE profile for ISIS NOW at Trade-IdeasMore details on ISIS: Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. Currently there are 3 analysts that rate Isis Pharmaceuticals a buy, 2 analysts rate it a sell, and 2 rate it a hold.The average volume for Isis Pharmaceuticals has been 1.5 million shares per day over the past 30 days. Isis has a market cap of $4.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.78 and a short float of 13.1% with 8.68 days to cover. Shares are up 265.3% year to date as of the close of trading on Tuesday.STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.TheStreetRatings.com Analysis:TheStreet Quant Ratings rates Isis Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.Highlights from the ratings report include:
- ISIS's very impressive revenue growth greatly exceeded the industry average of 11.3%. Since the same quarter one year prior, revenues leaped by 103.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- The current debt-to-equity ratio, 0.40, is low and is below the industry average, implying that there has been successful management of debt levels. Along with this, the company maintains a quick ratio of 7.27, which clearly demonstrates the ability to cover short-term cash needs.
- Net operating cash flow has significantly increased by 364.64% to $65.82 million when compared to the same quarter last year. In addition, ISIS PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of 1.54%.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ISIS PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- You can view the full Isis Pharmaceuticals Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV